Get all premium features to the best stock analysis tool

HONG KONG, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Cellyan Biotechnology Co., Ltd (Nasdaq: HKPD) (the "Company"), a leading provider of over the counter (“OTC”) pharmaceutical cross-border e-commerce supply chain services in Hong Kong, today announced that it received a notification letter (the “Notification Letter”) dated January 12, 2026 from Nasdaq's Listing Qualifications Department indicating that the closing bid price of the Company's class A ordinary shares of par value of US$0.001 each was below the minimum requirement of US$1.00 per share for 30 consecutive business days from November 26, 2025 through January 9, 2026, and the Company was therefore currently not in compliance with the minimum bid price requirement set forth under Nasdaq listing rule 5550(a)(2).  The notification letter has no immediate effect on the listing of the Company's class A ordinary shares, which will continue to trade uninterrupted on Nasdaq under the ticker “HKPD”.

HONG KONG, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ: HKPD) ("HKPD" or the "Company"), a leading provider of over the counter (“OTC”) pharmaceutical cross-border e-commerce supply chain services in Hong Kong, today announced that all proposals at the Company's 2025 annual meeting of stockholders held on December 12, 2025 local time were duly passed. The shareholders of the Company passed and approved the following proposals:

San Diego, California--(Newsfile Corp. - December 1, 2025) - Direct Communication Solutions, Inc. (CSE: DCSI) (FSE: 7QU0), a leading provider of information technology solutions for the Internet of Things (IoT) market, is excited to announce Q3'2025 revenues of USD $2.0 million versus USD $1.6 million in Q2'2024 representing an increase of 28% year over year. The nine months revenues ending September 2025, were reported at USD $7.2 million versus USD $4.9 million in 2024 representing an increase of 47%.